Current Research Interests

With over 25 years of experience in both the pharmaceutical industry and academic medical centers, Dr. Iasonos has dedicated her career to advancing oncology research and improving clinical trial outcomes. Her expertise spans from early drug development, safety and efficacy data analysis to clinical trial design, monitoring, reporting, and regulatory compliance.

Currently, Dr. Iasonos focuses on two key areas of research:

In addition, she is deeply involved in efforts to address global cancer disparities through her work with the Global Cancer Disparities Initiative at Memorial Sloan Kettering Cancer Center (MSKCC).

For the past two decades, Dr. Iasonos has worked closely with oncologists, surgeons, and pathologists in the Gynecology service, contributing to over 200 peer-reviewed articles and multiple presentations at scientific meetings. She has played a significant role in various clinical protocols, including vaccine trials in ovarian cancer and studies evaluating targeted therapies, immunotherapies, and CAR T-cell therapies. Part of this work has been funded by the Ovarian Program Project for which Dr Iasonos has served as the lead of the Biostatistics Core for a decade, and she has been part of numerous P01, R01 and SPORE applications in gynecological cancers.

Dr. Iasonos is also highly involved in clinical research governance. She has assumed several roles in compliance at her institution.  Among other responsibilities, Dr Iasonos has created and implemented several SOPs, identified, and trained new members for scientific protocol review committees and has served in leadership roles that review trial prioritization and clinical research administration. She is currently the chair of the Data Safety Monitoring Board at MSKCC and serves on several external DSMBs. As a co-chair of the Research Council, she has helped develop guidelines and policies to ensure the scientific integrity of clinical research protocols including sponsored trials. She has been an invited speaker on several FDA-AACR public workshops on optimizing dosages for oncology drug products or on tumor agnostic drug development.

On an international scale, Dr. Iasonos collaborates with leading research teams from institutions such as University College London, Sorbonne University, Heidelberg University Hospital, and African oncology research group to advance educational and research efforts, particularly in Nigeria.

An advocate for mentoring and career development, Dr. Iasonos has held leadership roles on the Junior Faculty Council and the Medical Staff Advisory Council (elected position) at MSKCC. She is a dedicated mentor to early and mid-career scientists and clinician scientists across various disciplines. She has recently received the Values in action innovation badge award from MSKCC for her mentorship of a start-up company as part of the MSK Innovation Hub Challenge. She recently completed her term as the Chair of the Continuing Education Committee of the American Statistical Association, Biometrics section.

In addition to her research and leadership roles, Dr. Iasonos is the Deputy Editor of the Journal of Clinical Oncology and an elected member of the Society of Clinical Trials Board of Directors. She has been honored with several prestigious awards, including Fellow of the American Society of Clinical Oncology (2024) and Fellow of the Society of Clinical Trials (2022). She has recently been elected as the president-elect of the Society of Clinical Trials (2025).